Justin Wiseman

Justin Wiseman Prosolia, Inc CEO

Justin is Chairman, President & CEO of Prosolia, Inc., an analytical instrument company specializing in innovative mass spectrometry solutions for life sciences. He also serves on the Board of Directors of Phlebotics, Inc., a medical device company developing automated blood sampling systems for personalized care. At Prosolia, Justin raised over $8M in dilutive and non-dilutive capital and led the sale of its DESI business to Waters Corporation in 2018.

Justin is an author of over forty peer-reviewed scientific publications and book chapters accumulating over 5000 citations on the subject of mass spectrometry. He is an inventor on five patents and has presented invited lectures worldwide on the subject of ambient mass spectrometry and molecular imaging for pathology.

Justin obtained a Ph.D. in Analytical Chemistry from Purdue University and completed the Applied Management Principles Executive Education program at Krannert School of Management. During his tenure at Purdue, Justin was the recipient of Schering Plough’s Science and Innovation Award for his work on the development and application of DESI mass spectrometry. In 2019 he was recognized by the College of Science at Purdue as outstanding alumni entrepreneur. Prior to pursuing his doctoral studies, Justin was an Analytical Chemist in Parenteral Quality Control at Eli Lilly and Company in Indianapolis, IN.